Cambrex is investing in a new, 21,000-sq.-ft. research and development facility in Minneapolis, MN, expanding capacity for small molecule development and manufacturing. Located near the Minneapolis–St. Paul Airport, the new facility will specialize in analytical and chemical development for pharmaceutical drug candidates and will operate as an extension of Cambrex’s flagship facility in Charles City, Iowa. Cambrex is expected to add approximately 40 new jobs over the next 2-3 years at the new site in Minneapolis.
 
Cambrex is also investing in a multi-phase, 9,000-sq.-ft. expansion and 21,000-sq.-ft. renovation project in Charles City, Iowa. The expansion will add a new quality control lab and administrative office space, which will bring 40 new jobs at the site. The renovations will enhance and modernize the existing quality control and research and development facilities.
 
“Our new facility in Minneapolis will double our analytical and chemical development footprint in the Midwest, providing clients with easy access to state-of-the-art capabilities and top scientific experts,” said Thomas Loewald, CEO of Cambrex. “We continue to invest in our U.S.-based footprint to support the demand for high-quality API development and manufacturing.”
 
This investment follows an earlier $50 million expansion in Charles City that was completed in the first quarter of 2022, establishing Cambrex as the largest active pharmaceutical ingredient (API) manufacturing site in the U.S. The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.